CYCLOPHARM LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.8 AUD | +2.86% |
|
+2.86% | -6.49% |
| Mar. 19 | Cyclopharm's Technegas Device Carries Out Imaging of First US Patients | MT |
| Mar. 18 | Cyclopharm Limited(ASX:CYC) added to S&P/ASX All Ordinaries Index | CI |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company returns high margins, thereby supporting business profitability.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -6.49% | 107M | - | ||
| +8.33% | 219B | B | ||
| +6.72% | 183B | B- | ||
| +10.18% | 132B | B- | ||
| +24.91% | 106B | A- | ||
| -0.95% | 62.09B | A- | ||
| +10.56% | 50.8B | B+ | ||
| +4.81% | 50.88B | B+ | ||
| -0.24% | 40.64B | A | ||
| +1.22% | 35.71B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CYC Stock
- Ratings Cyclopharm Limited
